|
Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline |
|
|
Employment - Texas Oncology |
Honoraria - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; GlaxoSmithKline; GlaxoSmithKline; Novartis; Pfizer |
Speakers' Bureau - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Pfizer |
Research Funding - GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Medivation (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Medivation; Millennium; Novartis |
Consulting or Advisory Role - AVEO; Eisai; Novartis; Pfizer |
Research Funding - Argos Therapeutics; Eisai; Millennium; Novartis; Pfizer; TRACON Pharma |
|
|
Consulting or Advisory Role - AVEO; Bayer/Onyx |
Research Funding - Eisai (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Eisai |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astra Zeneca, Amgen |
|
Research Funding - Roche, GSK (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Novartis; Pfizer; Roche Pharma AG |
Travel, Accommodations, Expenses - Novartis |
|
|
Honoraria - Bayer; Novartis; Pfizer |
Consulting or Advisory Role - Bayer; Novartis |
Travel, Accommodations, Expenses - Bayer; Novartis; Pfizer |
|
|
|
|
|
|
|
|
|
|
|
Research Funding - Novartis (Inst); Pfizer (Inst) |